How Alirocumab (Praluent) Affects ApoB Levels
Alirocumab (Praluent) reduces apolipoprotein B (ApoB) by 36 to 54% in clinical trials. Learn the mechanism, timeline, key trial data from ODYSSEY OUTCOMES, and when to monitor ApoB on Praluent.
How Alirocumab Affects Labs
3 source-based articles maintained by the HealthRX.com Editorial Team.
3articles
2topic areas covered
May 26, 2026latest review
How Alirocumab Affects Labs library
Showing 3 of 3 clinical reviews.
How Alirocumab (Praluent) Affects AST Levels
Alirocumab (Praluent) has minimal effect on AST in most patients. Learn what clinical trials show about Praluent and liver enzymes, when to monitor AST, and what elevations mean.
How Alirocumab (Praluent) Affects Lp(a): Mechanism, Magnitude, and Monitoring
Alirocumab (Praluent) lowers Lp(a) by roughly 20-30%. Learn the clinical evidence from ODYSSEY OUTCOMES, the PCSK9-mediated mechanism, expected time course, and when to check Lp(a) levels on therapy.